nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Advanced molecular imaging for the characterisation of complex medicines
|
Yilmaz, Duygu |
|
|
27 |
6 |
p. 1716-1723 |
artikel |
2 |
AI-based protein structure databases have the potential to accelerate rare diseases research: AlphaFoldDB and the case of IAHSP/Alsin
|
Rossi Sebastiano, Matteo |
|
|
27 |
6 |
p. 1652-1660 |
artikel |
3 |
Approaches for discovery of small-molecular antivirals targeting to influenza A virus PB2 subunit
|
Chen, Wenteng |
|
|
27 |
6 |
p. 1545-1553 |
artikel |
4 |
Contents page
|
|
|
|
27 |
6 |
p. i-ii |
artikel |
5 |
Defining clinical outcome pathways
|
Korn, Daniel |
|
|
27 |
6 |
p. 1671-1678 |
artikel |
6 |
Democratizing data at Novartis through clinical trial data access
|
Eichler, Gabriel S. |
|
|
27 |
6 |
p. 1533-1537 |
artikel |
7 |
Effects on bone regeneration of single-dose treatment with osteogenic small molecules
|
Lo, Kevin W.-H. |
|
|
27 |
6 |
p. 1538-1544 |
artikel |
8 |
Engineering nanobodies for next-generation molecular imaging
|
Yang, Erpeng |
|
|
27 |
6 |
p. 1622-1638 |
artikel |
9 |
Exploiting protease activation for therapy
|
Bleuez, Chloe |
|
|
27 |
6 |
p. 1743-1754 |
artikel |
10 |
Histone deacetylase inhibitor-based oncolytic virotherapy: A promising strategy for cancer treatment
|
Shirbhate, Ekta |
|
|
27 |
6 |
p. 1689-1697 |
artikel |
11 |
How nano-engineered delivery systems can help marketed and repurposed drugs in Alzheimer’s disease treatment?
|
Séguy, Line |
|
|
27 |
6 |
p. 1575-1589 |
artikel |
12 |
Machine learning to design antimicrobial combination therapies: Promises and pitfalls
|
Cantrell, Jennifer M. |
|
|
27 |
6 |
p. 1639-1651 |
artikel |
13 |
Mechanisms of antidiabetic drugs and cholesterol efflux: A clinical perspective
|
Ahmadi, Ali |
|
|
27 |
6 |
p. 1679-1688 |
artikel |
14 |
Nanomedicine for overcoming therapeutic and diagnostic challenges associated with pancreatic cancer
|
Iyengar, Disha |
|
|
27 |
6 |
p. 1554-1559 |
artikel |
15 |
New therapy strategies in the management of breast cancer
|
Yardim-Akaydin, Sevgi |
|
|
27 |
6 |
p. 1755-1762 |
artikel |
16 |
Oncological drug discovery: AI meets structure-based computational research
|
Gorostiola González, Marina |
|
|
27 |
6 |
p. 1661-1670 |
artikel |
17 |
Orphan drug development: The impact of regulatory and reimbursement frameworks
|
Huang, Yu-Jun |
|
|
27 |
6 |
p. 1724-1732 |
artikel |
18 |
Patents, trade secrets and pricing
|
Kinch, Michael S. |
|
|
27 |
6 |
p. 1531-1532 |
artikel |
19 |
Real-world data in drug development strategies for orphan drugs: Tafasitamab in B-cell lymphoma, a case study for an approval based on a single-arm combination trial
|
Serrano, Philippe |
|
|
27 |
6 |
p. 1706-1715 |
artikel |
20 |
Recent advances in metabolomics analysis for early drug development
|
Alarcon-Barrera, Juan Carlos |
|
|
27 |
6 |
p. 1763-1773 |
artikel |
21 |
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds
|
Proj, Matic |
|
|
27 |
6 |
p. 1733-1742 |
artikel |
22 |
Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory
|
Beck, Hartmut |
|
|
27 |
6 |
p. 1560-1574 |
artikel |
23 |
Stimuli-sensitive drug delivery systems for site-specific antibiotic release
|
Nazir, Faiqa |
|
|
27 |
6 |
p. 1698-1705 |
artikel |
24 |
Translating pharmacology models effectively to predict therapeutic benefit
|
Dudal, Sherri |
|
|
27 |
6 |
p. 1604-1621 |
artikel |
25 |
Ultrasound-activated nanomaterials for sonodynamic cancer theranostics
|
Wu, Nan |
|
|
27 |
6 |
p. 1590-1603 |
artikel |
26 |
Unraveling antimicrobial resistance using metabolomics
|
Kok, Maik |
|
|
27 |
6 |
p. 1774-1783 |
artikel |